Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas

Liya Yuan, Kihang Choi, Chaitan Khosla, Xiao Zheng, Ryuji Higashikubo, Michael R. Chicoine, Keith M. Rich

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Tissue transglutaminase 2 belongs to a family of transglutaminase proteins that confers mechanical resistance from proteolysis and stabilizes proteins. Transglutaminase 2 promotes transamidation between glutamine and lysine residues with the formation of covalent linkages between proteins. Transglutaminase 2 also interacts and forms complexes with proteins important in extracellular matrix organization and cellular adhesion. We have identified the novel finding that treatment of glioblastoma cells with transglutaminase 2 inhibitors promotes cell death and enhances sensitivity to chemotherapy. Treatment with either the competitive transglutaminase 2 inhibitor, monodansylcadaverine, or with highly specific small-molecule transglutaminase 2 inhibitors, KCA075 or KCC009, results in induction of apoptosis in glioblastoma cells. Treatment with these transglutaminase 2 inhibitors resulted in markedly decreased levels of the prosurvival protein, phosphorylated Akt, and its downstream targets. These changes promote a proapoptotic profile with altered levels of multiple intracellular proteins that determine cell survival. These changes include decreased levels of the antiapoptotic proteins, survivin, phosphorylated Bad, and phosphorylated glycogen synthetase kinase 3β (GSK-3β), and increased levels of the proapoptotic BH3-only protein, Bim. In vivo studies with s.c. murine DBT glioblastoma tumors treated with transglutaminase 2 inhibitors combined with the chemotherapeutic agent, N-N′-bis (2-chloroethyl)-N-nitrosourea (BCNU), decreased tumor size based on weight by 50% compared with those treated with BCNU alone. Groups treated with transglutaminase 2 inhibitors showed an increased incidence of apoptosis determined with deoxynucleotidyl transferase - mediated biotin nick-end labeling staining. These studies identify inhibition of transglutaminase 2 as a potential target to enhance cell death and chemosensitivity in glioblastomas.

Original languageEnglish
Pages (from-to)1293-1302
Number of pages10
JournalMolecular Cancer Therapeutics
Volume4
Issue number9
DOIs
Publication statusPublished - 2005 Sep 1
Externally publishedYes

Fingerprint

Glioblastoma
Cell Death
Proteins
Carmustine
transglutaminase 2
Apoptosis
Glycogen Synthase
Transglutaminases
DNA Nucleotidylexotransferase
Biotin
Glutamine
Proteolysis
Lysine
Extracellular Matrix
Neoplasms
Cell Survival
Phosphotransferases
Therapeutics
Staining and Labeling
Weights and Measures

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. / Yuan, Liya; Choi, Kihang; Khosla, Chaitan; Zheng, Xiao; Higashikubo, Ryuji; Chicoine, Michael R.; Rich, Keith M.

In: Molecular Cancer Therapeutics, Vol. 4, No. 9, 01.09.2005, p. 1293-1302.

Research output: Contribution to journalArticle

Yuan, Liya ; Choi, Kihang ; Khosla, Chaitan ; Zheng, Xiao ; Higashikubo, Ryuji ; Chicoine, Michael R. ; Rich, Keith M. / Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 9. pp. 1293-1302.
@article{5f30cf4ed4fe4d1cb15b262fe21b2a1f,
title = "Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas",
abstract = "Tissue transglutaminase 2 belongs to a family of transglutaminase proteins that confers mechanical resistance from proteolysis and stabilizes proteins. Transglutaminase 2 promotes transamidation between glutamine and lysine residues with the formation of covalent linkages between proteins. Transglutaminase 2 also interacts and forms complexes with proteins important in extracellular matrix organization and cellular adhesion. We have identified the novel finding that treatment of glioblastoma cells with transglutaminase 2 inhibitors promotes cell death and enhances sensitivity to chemotherapy. Treatment with either the competitive transglutaminase 2 inhibitor, monodansylcadaverine, or with highly specific small-molecule transglutaminase 2 inhibitors, KCA075 or KCC009, results in induction of apoptosis in glioblastoma cells. Treatment with these transglutaminase 2 inhibitors resulted in markedly decreased levels of the prosurvival protein, phosphorylated Akt, and its downstream targets. These changes promote a proapoptotic profile with altered levels of multiple intracellular proteins that determine cell survival. These changes include decreased levels of the antiapoptotic proteins, survivin, phosphorylated Bad, and phosphorylated glycogen synthetase kinase 3β (GSK-3β), and increased levels of the proapoptotic BH3-only protein, Bim. In vivo studies with s.c. murine DBT glioblastoma tumors treated with transglutaminase 2 inhibitors combined with the chemotherapeutic agent, N-N′-bis (2-chloroethyl)-N-nitrosourea (BCNU), decreased tumor size based on weight by 50{\%} compared with those treated with BCNU alone. Groups treated with transglutaminase 2 inhibitors showed an increased incidence of apoptosis determined with deoxynucleotidyl transferase - mediated biotin nick-end labeling staining. These studies identify inhibition of transglutaminase 2 as a potential target to enhance cell death and chemosensitivity in glioblastomas.",
author = "Liya Yuan and Kihang Choi and Chaitan Khosla and Xiao Zheng and Ryuji Higashikubo and Chicoine, {Michael R.} and Rich, {Keith M.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1158/1535-7163.MCT-04-0328",
language = "English",
volume = "4",
pages = "1293--1302",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas

AU - Yuan, Liya

AU - Choi, Kihang

AU - Khosla, Chaitan

AU - Zheng, Xiao

AU - Higashikubo, Ryuji

AU - Chicoine, Michael R.

AU - Rich, Keith M.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Tissue transglutaminase 2 belongs to a family of transglutaminase proteins that confers mechanical resistance from proteolysis and stabilizes proteins. Transglutaminase 2 promotes transamidation between glutamine and lysine residues with the formation of covalent linkages between proteins. Transglutaminase 2 also interacts and forms complexes with proteins important in extracellular matrix organization and cellular adhesion. We have identified the novel finding that treatment of glioblastoma cells with transglutaminase 2 inhibitors promotes cell death and enhances sensitivity to chemotherapy. Treatment with either the competitive transglutaminase 2 inhibitor, monodansylcadaverine, or with highly specific small-molecule transglutaminase 2 inhibitors, KCA075 or KCC009, results in induction of apoptosis in glioblastoma cells. Treatment with these transglutaminase 2 inhibitors resulted in markedly decreased levels of the prosurvival protein, phosphorylated Akt, and its downstream targets. These changes promote a proapoptotic profile with altered levels of multiple intracellular proteins that determine cell survival. These changes include decreased levels of the antiapoptotic proteins, survivin, phosphorylated Bad, and phosphorylated glycogen synthetase kinase 3β (GSK-3β), and increased levels of the proapoptotic BH3-only protein, Bim. In vivo studies with s.c. murine DBT glioblastoma tumors treated with transglutaminase 2 inhibitors combined with the chemotherapeutic agent, N-N′-bis (2-chloroethyl)-N-nitrosourea (BCNU), decreased tumor size based on weight by 50% compared with those treated with BCNU alone. Groups treated with transglutaminase 2 inhibitors showed an increased incidence of apoptosis determined with deoxynucleotidyl transferase - mediated biotin nick-end labeling staining. These studies identify inhibition of transglutaminase 2 as a potential target to enhance cell death and chemosensitivity in glioblastomas.

AB - Tissue transglutaminase 2 belongs to a family of transglutaminase proteins that confers mechanical resistance from proteolysis and stabilizes proteins. Transglutaminase 2 promotes transamidation between glutamine and lysine residues with the formation of covalent linkages between proteins. Transglutaminase 2 also interacts and forms complexes with proteins important in extracellular matrix organization and cellular adhesion. We have identified the novel finding that treatment of glioblastoma cells with transglutaminase 2 inhibitors promotes cell death and enhances sensitivity to chemotherapy. Treatment with either the competitive transglutaminase 2 inhibitor, monodansylcadaverine, or with highly specific small-molecule transglutaminase 2 inhibitors, KCA075 or KCC009, results in induction of apoptosis in glioblastoma cells. Treatment with these transglutaminase 2 inhibitors resulted in markedly decreased levels of the prosurvival protein, phosphorylated Akt, and its downstream targets. These changes promote a proapoptotic profile with altered levels of multiple intracellular proteins that determine cell survival. These changes include decreased levels of the antiapoptotic proteins, survivin, phosphorylated Bad, and phosphorylated glycogen synthetase kinase 3β (GSK-3β), and increased levels of the proapoptotic BH3-only protein, Bim. In vivo studies with s.c. murine DBT glioblastoma tumors treated with transglutaminase 2 inhibitors combined with the chemotherapeutic agent, N-N′-bis (2-chloroethyl)-N-nitrosourea (BCNU), decreased tumor size based on weight by 50% compared with those treated with BCNU alone. Groups treated with transglutaminase 2 inhibitors showed an increased incidence of apoptosis determined with deoxynucleotidyl transferase - mediated biotin nick-end labeling staining. These studies identify inhibition of transglutaminase 2 as a potential target to enhance cell death and chemosensitivity in glioblastomas.

UR - http://www.scopus.com/inward/record.url?scp=33644668017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644668017&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-04-0328

DO - 10.1158/1535-7163.MCT-04-0328

M3 - Article

VL - 4

SP - 1293

EP - 1302

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -